Tumor Biology

, Volume 37, Issue 6, pp 7507–7514

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

  • Young Wha Koh
  • Yoon Kyung Jeon
  • Dok Hyun Yoon
  • Cheolwon Suh
  • Jooryung Huh
Original Article

DOI: 10.1007/s13277-015-4622-5

Cite this article as:
Koh, Y.W., Jeon, Y.K., Yoon, D.H. et al. Tumor Biol. (2016) 37: 7507. doi:10.1007/s13277-015-4622-5

Abstract

Programmed cell death protein-1 (PD-1) inhibitor may be therapeutic in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL). This study examined the prognostic significance of PD-1 and two PD-1 ligands (PD-L1 and PD-L2) in uniformly treated cHL. Diagnostic tissues from 109 cHL patients treated with a doxorubicin, bleomycin, vinblastine, and dacarbazine regimen were evaluated retrospectively by immunohistochemical analysis of PD-L1, PD-L2, and PD-1 expressions. The median follow-up time was 4.91 years (range, 0.17–17.33 years). Thirteen patients (11 %) expressed PD-1 protein in the peritumoral microenvironment, which was associated with poor overall survival (OS) (P = 0.017). PD-L1 or PD-L2 expression was not associated with OS. There was no correlation between PD-L1 and PD-1 expression or between PD-L2 and PD-1 expression. Multivariate analysis identified PD-1 protein as an independent prognostic factor for OS (P = 0.019). Subgroup analysis according to the Ann Arbor stage of cHL showed that PD-1 protein expression had a prognostic value in limited-stage cHL (P = 0.048). PD-1 is an independent prognostic factor in cHL and may allow the identification of a subgroup of patients with limited-stage cHL who require more intensive therapy and who may benefit from anti-PD-1 agents.

Keywords

Hodgkin’s lymphoma PD-L1 PD-L2 PD-1 Prognosis 

Supplementary material

13277_2015_4622_MOESM1_ESM.docx (17 kb)
ESM 1(DOCX 17 kb)

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Young Wha Koh
    • 1
  • Yoon Kyung Jeon
    • 2
  • Dok Hyun Yoon
    • 3
  • Cheolwon Suh
    • 3
  • Jooryung Huh
    • 4
  1. 1.Department of PathologyAjou University School of MedicineSuwonSouth Korea
  2. 2.Department of PathologySeoul National University HospitalSeoulSouth Korea
  3. 3.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  4. 4.Department of Pathology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea